Mike Coyle Steps Down As iRhythm CEO; CFO Douglas Devine Will Be Interim CEO

Douglas Devine will take over as interim CEO as iRhythm tries to resolve reimbursement challenges and roll out the next generation of its Zio remote cardiac monitor with an updated artificial intelligence system.

Business leader builds a tower block with employees. Team building, hierarchical power vertical system. Leadership. Effective team Management. Company - Image ID: 2CA4KEM
• Source: Alamy

Cardiac monitoring company iRhythm Technologies announced an unexpected change in leadership on 1 June.

Mike Coyle resigned as CEO, president and member of the company’s board, citing his need to attend to personal matters. Douglas Devine, iRhythm’s chief financial officer, will be the interim CEO while the company searches for a permanent CEO

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from Medtech Insight

Faster Device Certification Among Keys To Unlocking Innovation In EU MedTech Sector

 

While MedTech Europe sharpens its focus on what the EU most urgently needs to advance the medtech market in four targeted measures, the European Commission has also unveiled four priorities for 2025.

GE HealthCare Warns Of $500M Tariff Hit In 2025, Eyes Recovery in 2026

 
• By 

GE HealthCare anticipates most of the $0.85 EPS tariff impact will play out in the second half of 2025. Jay Saccaro, vice president and CFO, said the tariff-related burden is minimal in Q1 at about $10 million, rising to nearly $100 million in Q2 and then spiking to around $200 million each in Q3 and Q4.

Peerbridge Bets On At-Home Heart Monitoring With Rechargeable, Longer-Lasting ECG Patch

 
• By 

Peerbridge Health is preparing to submit its next-generation ECG patch, CorMDx, for US FDA clearance this quarter, with plans to launch in the second half of 2025. The rechargeable device is designed for continuous, real-time heart monitoring from the hospital to home, aiming to detect early signs of heart failure and reduce emergency room visits.